Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes: Focus on sitagliptin
Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes: Focus on sitagliptin
复制标题
DOI：
10.1038/sj.clpt.6100167
复制
发表时间：
2007-05-01
影响因子：
6.7
通讯作者：
Wagner, J. A.
中科院分区：
文献类型：
--
作者：
Herman, G. A.;Stein, P. P.;Wagner, J. A.
二肽基肽酶-4 （DPP-4）抑制剂是治疗2型糖尿病患者的一种新型口服降糖药物。1 DPP-4抑制剂改善空腹和餐后血糖控制，无低血糖或体重增加。本文重点介绍了DPP-4抑制剂西格列汀在2型糖尿病治疗中的生理学、临床药理学、耐受性和临床应用。
Dipeptidyl peptidase-4 ( DPP-4) inhibitors represent a new class of oral antihyperglycemic agents to treat patients with type 2 diabetes. 1 DPP-4 inhibitors improve fasting and postprandial glycemic control without hypoglycemia or weight gain. 1 This article focuses on the physiology, clinical pharmacology, tolerability, and clinical utility of the DPP-4 inhibitor sitagliptin in the management of type 2 diabetes.